The FDA has approved Teva’s UZEDY for the treatment of bipolar I disorder in adults. This extended-release injectable suspension can be used alone or with lithium/valproate. Administered once every one or two months, UZEDY utilizes Medincell’s SteadyTeq copolymer technology for controlled drug release. It achieves therapeutic blood levels within 6 to 24 hours. Available in three dosing strengths, it was previously approved for schizophrenia. TEVA’s stock closed at $20.03 on Friday. UZEDY was approved in 2023 for schizophrenia. Visit rttnews.com for more health news. (Word count: 74)

Read more at Nasdaq.: Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults